Aristea Therapeutics Raises $15M to Develop Anti-Inflammatory Drugs

New biopharma company Aristea Therapeutics has raised $15 million from Novo Holdings, the Danish investment company, and secured global rights to an investigational AstraZeneca drug that?s ready for Phase 2 study. The San Diego, CA, company made its public debut this week after starting up quietly earlier this year. Aristea expects its lead program, RIST4721, [?]